Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

20142,016 citationsJournal Articlebronze Open Access

Authors

James Larkin · Ospedale Papa Giovanni XXIII

Paolo A. Ascierto

Luis de la Cruz‐Merino

Caroline Dutriaux

Abstract

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.).

Topics & Keywords

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 20, pp. 1867-1876

DOI: 10.1056/nejmoa1408868

Field-Weighted Citation Impact: 103.07